Since originally publishing this article in September 2021, selegiline has been discontinued and supplies have been depleted. Rasagiline is now the only funded MAO-B inhibitor available in New Zealand.

This resource provides advice on prescribing and supplying rasagiline, which is currently funded but not yet approved by Medsafe.